Displaying drugs 14826 - 14850 of 15052 in total
PVX-410 component CD138 260-268(GLVGLIFAV)
Investigational
MB-107
MB-107 consists of mobilized peripheral blood-derived autologous CD34+ hematopoietic stem cells that are genetically modified to express the IL2RG gene.
Investigational
B7-H3-specific chimeric antigen receptor T cells
Investigational
SPL84-23-1
SPL84-23-1 is a sodium salt of 19-bp single-stranded RNA uniformly modified 2'-O-(2-methoxyethyl) phosphorothioate Antisense Oligonucleotide (ASO) consisting of 19 nucleotide residues with the sequence 5'-5MeC-5MeU-G-5MeC-A-A-5MeC-A-G-A-5MeU-G-G-A-A-G-A-5MeC-5MeU-3'
Investigational
PBFT02
PBFT02 is a non-replicating recombinant adeno-associated virus serotype 1 vector delivering human GRN gene encoding the protein progranulin.
Investigational
scAAV9.U7.ACCA
scAAV9.U7.ACCA is a non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA. Developed by Nationwide Children’s Hospital, it is being investigated for the treatment of Duchenne muscular dystrophy.
Investigational
WU-CART-007
WU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.
Investigational
CMG901
CMG901 is an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload.
Investigational
CTX120
CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.
Investigational
CTX110
CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.
Investigational
ALLO-715
ALLO-715 is an allogeneic chimeric antigen receptor T Cell therapy targeting B cell maturation antigen (BCMA).
Investigational
ALLO-605
ALLO-605 is an allogeneic turbo chimeric antigen receptor (Turbocar) T Cell therapy targeting B Cell maturation antigen (BCMA).
Investigational
AVR-RD-04
AVR-RD-04 is an investigational gene therapy for cystinosis. It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin.
Investigational
Allogenic fetal mesenchymal stem cells
Investigational
HUB-101
Investigational
RGG0853
RGG0853 is an E1A lipid complex, a repressor gene complexed with a cationic lipid vector.
Investigational
Ozekibart
Ozekibart is a tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5). It is being investigated for the treatment of chondrosarcoma.
Investigational
MBP134
MBP134 is a pan-ebolavirus cocktail comprising two broadly neutralizing human antibodies. It is under investigation for the treatment of Sudan ebolavirus (SUDV).
Investigational
EDIT-101
EDIT-101 is a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing constructs.
Investigational
Cellspan Esophageal Implant
The Cellspan Esophageal ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a polyurethane tubular mesh cell delivery device.
Investigational
ISA101b
ISA101b (peltopepimut-S) is a therapeutic vaccine against the HPV-specific E6/E7 oncoproteins.
Investigational
Displaying drugs 14826 - 14850 of 15052 in total